Segmentable Gabapentin Tablets for Stable Veterinary Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing veterinary compositions for gabapentin administration in animals lack stability and efficacy, often leading to toxicity issues, and there is a need for safe, effective oral formulations that can be easily adjusted for different animal sizes and weights.
Innovation Solution
A solid veterinary pharmaceutical composition comprising gabapentin, silicon dioxide or colloidal silicon dioxide, sorbitan monolaurate, and pharmaceutically acceptable excipients, formulated as segmentable tablets to ensure stability and efficacy, with each segment having consistent physical, chemical, and therapeutic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional veterinary compositions are used for gabapentin administration, then the formulation is simpler to manufacture, but the stability and efficacy are insufficient leading to toxicity issues
Solution Approach 1:
The patent uses a composite formulation combining gabapentin with specific excipients including silicon dioxide (10-80% of total weight), sorbitan monolaurate (1-20% of total weight), and various pharmaceutically acceptable excipients. This composite approach enhances stability and efficacy while avoiding toxicity, resolving the contradiction between reliability and ease of manufacture.
2Adaptability or versatility
If fixed-dose formulations are used, then the manufacturing process is simpler, but the adaptability to different animal sizes and weights is limited
Solution Approach 1:
The patent formulates gabapentin as segmentable tablets that can be divided into multiple portions. This allows veterinarians to adjust the dose according to the animal's size and weight by administering appropriate numbers of segments, thereby achieving adaptability while maintaining a relatively simple manufacturing process for the base tablet structure.
3Reliability
If higher concentrations of gabapentin are used to ensure efficacy, then the therapeutic effect is improved, but the risk of toxicity increases
Solution Approach 1:
The patent optimizes the concentration of gabapentin within a specific range (1 to 1000 mg per dosage unit) and carefully controls the ratios of excipients, particularly silicon dioxide (10-80%) and sorbitan monolaurate (1-20%). This parameter optimization ensures therapeutic efficacy while minimizing toxicity risk through improved stability and controlled release characteristics.
4Ease of operation
If segmentable tablets are formulated to allow dose adjustment, then the ease of operation for different animal sizes is improved, but the manufacturing precision requirements increase
Solution Approach 1:
The patent designs tablets with inherent segmentability through careful formulation of excipients including silicon dioxide and sorbitan monolaurate. The segmentation is achieved during the manufacturing process by creating tablets with defined fracture planes or by producing multiple smaller tablets of consistent dosage, ensuring that each segment maintains uniform physical and chemical properties while allowing flexible administration.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a solid veterinary pharmaceutical composition, of oral administration comprising: a) a drug selected from gabapentin and/or fluoxetine or a pharmaceutically acceptable salt thereof, preferably gabapentin or an acceptable salt thereof in a concentration from 10 to 1000 mg; b) from 10% to 80% of the composition total weight of at least one silicon salt selected preferably from silicon dioxide, colloidal silicon dioxide, calcium silicate, magnesium silicate or combinations thereof; c) from 1% to 20% of the composition total weight of at least one polyoxyethylenated sorbitan ester, preferably selected from sorbitan monolaurate, sorbitan monooleate and sorbitan trioleate, or combinations thereof; and d) one or more pharmaceutically acceptable excipients; such that it is optimally prepared as a veterinary pharmaceutical product that exhibits safety and efficacy in mammalian animals, preferably in companion animals.